Newsletter | February 22, 2021

02.22.21 -- What It Takes To Start A Biopharma Company

 
Sponsor
Featured Articles
My Journey From Skepticism To Conviction Regarding AI
 

How artificial intelligence (AI) is bridging the gap between technology and biology in drug development.

From Medical Researcher To CEO
 

Yan Chen used her industry experience and interest in immunology to start Elpis Biopharmaceuticals, a company hoping to find cures for difficult-to-treat cancers.

Number Of EDC Systems Used: Current And Projected
 

In our most recent survey of electronic data capture (EDC) users, respondents indicated they are currently using 2.4 EDC systems on average to conduct their companies’ clinical trials.

Video
Sponsor
Web-Exclusive Content
Research Report Shows Phase 2/3 Spending Will Increase
 

Research firm Industry Standard Research recently published its Phase II/III Study Trends and Market Outlook report. The goal of this report is to provide readers with a high-level view of the Phase 2/3 clinical development space to illustrate current market dynamics and inform strategic planning.

Podcasts
025: Are Decentralized Trials Finally Here To Stay?
 
Will decentralized clinical trials continue to be a hot topic even after the pandemic, or will pharma companies revert to their old ways? Our guest, ClinicalLeader.com editor, Ed Miseta, weighs in on this timely topic.
e-books
Companies To Watch: 2020
 

In 2020 we profiled 11 biopharma companies in our “Companies To Watch” section. These companies focused on a range of therapeutics including antifungals, antibody therapeutics for immunological diseases, and multiple antivirals and vaccines related to COVID-19.

February 2021 Digital Edition
 

Inside you will find more on:

  • CEO Corner
  • Clinical Trials
  • Leadership Lessons
  • Companies To Watch

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines
 

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.